244 related articles for article (PubMed ID: 11362229)
1. Sense antisense nonantisense. Can these novel antivirals knock HIV senseless?
Chang HE; Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Feb; 1(1):11-8. PubMed ID: 11362229
[TBL] [Abstract][Full Text] [Related]
2. ICAAC: what else is new?
Prescott LM
Posit Aware; 1996; 7(1):10-1. PubMed ID: 11363114
[TBL] [Abstract][Full Text] [Related]
3. Still looking for the real GEM.
GMHC Treat Issues; 1996 Apr; 10(4):9. PubMed ID: 11363711
[TBL] [Abstract][Full Text] [Related]
4. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
Orr RM
Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
[TBL] [Abstract][Full Text] [Related]
5. Significant inhibitory effects of Hybridon's antisense compound on various HIV-1 replication steps in in vitro tests.
AIDS Patient Care STDS; 1996 Dec; 10(6):375-6. PubMed ID: 11361558
[No Abstract] [Full Text] [Related]
6. First oligonucleotide in U.S. clinical trials for CMV retinitis.
AIDS Patient Care STDS; 1997 Jun; 11(3):198-9. PubMed ID: 11361805
[No Abstract] [Full Text] [Related]
7. Clinical trial results of GEM91 show activity against advance HIV.
AIDS Patient Care STDS; 1997 Aug; 11(4):290-1. PubMed ID: 11361850
[No Abstract] [Full Text] [Related]
8. Hairpin antisense oligonucleotides containing 2'-methoxynucleosides with base-pairing in the stem region at the 3'-end: penetration, localization, and Anti-HIV activity.
Kuwasaki T; Hosono K; Takai K; Ushijima K; Nakashima H; Saito T; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1996 Nov; 228(2):623-31. PubMed ID: 8920960
[TBL] [Abstract][Full Text] [Related]
9. Oligonucleotides as inhibitors of human immunodeficiency virus.
Field AK
Curr Opin Mol Ther; 1999 Jun; 1(3):323-31. PubMed ID: 11713797
[TBL] [Abstract][Full Text] [Related]
10. Fomivirsen approved for CMV retinitis.
Roehr B
J Int Assoc Physicians AIDS Care; 1998 Oct; 4(10):14-6. PubMed ID: 11365956
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 replication by triple-helix-forming phosphorothioate oligonucleotides targeted to the polypurine tract.
Tsukahara S; Suzuki J; Hiratou T; Takai K; Koyanagi Y; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1997 Apr; 233(3):742-7. PubMed ID: 9168925
[TBL] [Abstract][Full Text] [Related]
12. [New treatments for HIV].
Garcia E
Sidahora; 1996; ():48-50. PubMed ID: 11363630
[TBL] [Abstract][Full Text] [Related]
13. GEM 91--an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS.
Agrawal S; Tang JY
Antisense Res Dev; 1992; 2(4):261-6. PubMed ID: 1363378
[No Abstract] [Full Text] [Related]
14. New CMV drug won't replace other therapies.
AIDS Alert; 1998 Nov; 13(11):124-6. PubMed ID: 11365968
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus retinitis.
Bright DC
Optometry; 2001 Mar; 72(3):146-7. PubMed ID: 11294585
[No Abstract] [Full Text] [Related]
16. Antisense drug closer to approval.
AIDS Patient Care STDS; 1998 Oct; 12(10):805-6. PubMed ID: 11362033
[No Abstract] [Full Text] [Related]
17. First "antisense" drug will treat CMV retinitis.
Marwick C
JAMA; 1998 Sep; 280(10):871. PubMed ID: 9739955
[No Abstract] [Full Text] [Related]
18. Oligonucleotides as antivirals: dream or realistic perspective?
Van Aerschot A
Antiviral Res; 2006 Sep; 71(2-3):307-16. PubMed ID: 16621039
[TBL] [Abstract][Full Text] [Related]
19. NONAC update. CMV is still a threat in HIV; treatment guidelines change. New Orleans Nurses In AIDS Care.
Jarrott CR
Fac Notes (New Orleans La); 1999; 11(2):5. PubMed ID: 11816501
[No Abstract] [Full Text] [Related]
20. Advances in antisense efficacy and delivery.
Agrawal S; Akhtar S
Trends Biotechnol; 1995 Jun; 13(6):197-9. PubMed ID: 7598842
[No Abstract] [Full Text] [Related]
[Next] [New Search]
